加载中
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
收盘时
US$1.02
+US$0.02 · +2.00%
盘后
US$1.05
+US$0.03 · +2.94%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
日内区间
当前US$1.02
52周区间
当前US$1.02
盘中时间采用ET。市场数据可能有所延迟。
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
日内区间
当前US$1.02
52周区间
当前US$1.02
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2521万 USD | 5229.5万 USD | 4475.6万 USD | 1720万 USD | 24.3万 USD |
| 销货成本 | 531.7万 USD | — | 9440.3万 USD | 173.3万 USD | 38.7万 USD |
| 毛利 | 1989.3万 USD | 5229.5万 USD | −4964.7万 USD | 1546.7万 USD | −14.4万 USD |
| 研究与开发 | 9443.3万 USD | 1.09亿 USD | 9440.3万 USD | 4313.9万 USD | 1447.8万 USD |
| 销售、一般及管理费用 | 2679万 USD | 3201.7万 USD | 2884.5万 USD | 1870.1万 USD | 971.2万 USD |
| 营业费用 | 1.16亿 USD | 1.41亿 USD | 2884.5万 USD | 6010.7万 USD | 2380.3万 USD |
| 利息收入 | 947万 USD | 1472.2万 USD | 1546.8万 USD | 341.9万 USD | 4.3万 USD |
| 利息支出 | — | — | — | 9.8万 USD | 30.2万 USD |
| 折旧和摊销 | 531.7万 USD | 540.7万 USD | 420.7万 USD | 173.3万 USD | 38.7万 USD |
| 营业利润 | −9601.3万 USD | −8890.1万 USD | −7849.2万 USD | −4464万 USD | −2394.7万 USD |
| 净利润 | −8786.8万 USD | −7805.8万 USD | −6825.5万 USD | −4359.3万 USD | −2144.2万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$14.50
上涨空间 1321.57%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI87.49万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF37.22万0.00%954亿 USD0.05%US$233.52-0.63%
iShares Micro-Cap ETFIWC9.05万0.01%13.17亿 USD0.60%US$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM4万0.03%1.17亿 USD0.73%US$15.8484-0.58%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
